UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

1033 - The role of abiraterone acetate plus prednisone/prednisolone in high- and low-risk metastatic hormone sensitive prostate cancer

European urology supplements : official journal of the European Association of Urology, 2019-03, Vol.18 (1), p.e1387-e1388

2019

Volltextzugriff (PDF)

The 12C(p,2p)11B Reaction at 100 MeV

Australian journal of physics, 1979, Vol.32 (4), p.323

1979

Volltextzugriff (PDF)

1358O Clinical qualification of transcriptome signatures for advanced prostate cancer (APC) starting androgen deprivation therapy (ADT) with or without abiraterone acetate and prednisolone (AAP): An ancillary study of the STAMPEDE AAP trial

Annals of oncology, 2022-09, Vol.33, p.S1161

2022

Volltextzugriff (PDF)

1359MO Differential treatment response with nodal metastases in metastatic hormone-sensitive prostate cancer (mHSPC) and evaluation of nodal (N) burden as a prognostic biomarker: Ancillary studies of the docetaxel and abiraterone acetate and prednisolone (AAP) phase III trials from STAMPEDE

Annals of oncology, 2022-09, Vol.33, p.S1161-S1162

2022

Volltextzugriff (PDF)

158 POSTER Abiraterone acetate (AA), an irreversible inhibitor of CYP17, has significant and durable anti-tumor activity in both chemotherapy- naive and docetaxel treated castration-resistant prostate cancer (CRPC)

European journal of cancer supplements, 2008, Vol.6 (12), p.51-51

2008

Volltextzugriff (PDF)

158MO Niraparib with abiraterone acetate and prednisone (NIRA+AAP) as first-line therapy in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) with homologous recombination repair (HRR+) gene alterations: Asian subgroup analysis of the MAGNITUDE study

Annals of oncology, 2022-11, Vol.33, p.S1496-S1496

2022

Volltextzugriff (PDF)

159 POSTER Re-inducing sensitivity to abiraterone acetate, a novel CYP17 inhibitor with a high level of anti-tumour activity in castration resistant prostrate cancer

European journal of cancer supplements, 2008, Vol.6 (12), p.51-51

2008

Volltextzugriff (PDF)

1596O Decipher mRNA score for prediction of survival benefit from docetaxel at start of androgen deprivation therapy (ADT) for advanced prostate cancer (PC): An ancillary study of the STAMPEDE docetaxel trials

Annals of oncology, 2024-09, Vol.35, p.S961-S962

2024

Volltextzugriff (PDF)

1647P Clinical validity of plasma DNA testing to identify BRCA-mutated (BRCA+) patients in the MAGNITUDE study

Annals of oncology, 2024-09, Vol.35, p.S993-S993

2024

Volltextzugriff (PDF)

1656TiP The STAMPEDE2 niraparib-abiraterone acetate + prednisolone trial: A phase III, randomised, open-label trial in patients with metastatic prostate cancer (mPC) with a deleterious alteration in a homologous recombination repair (HRR) gene starting androgen deprivation therapy (ADT)

Annals of oncology, 2024-09, Vol.35, p.S998-S999

2024

Volltextzugriff (PDF)

1657TiP The STAMPEDE2 stereotactic ablative body radiotherapy (SABR) trial: A phase III, randomised, open-label trial in patients with newly diagnosed oligometastatic prostate cancer (PC) starting androgen deprivation therapy (ADT)

Annals of oncology, 2024-09, Vol.35, p.S999-S999

2024

Volltextzugriff (PDF)

1658TiP The STAMPEDE2 177Lutetium-PSMA-617 (177Lu-PSMA-617) trial: A phase III, randomised, open-label trial in patients with metastatic prostate cancer (mPC) starting androgen deprivation therapy (ADT)

Annals of oncology, 2024-09, Vol.35, p.S999-S1000

2024

Volltextzugriff (PDF)

1770O Refining risk stratification in patients undergoing radiotherapy (RT) and long-term (lt) ADT for high-risk/locally advanced prostate cancer (HR/LA-PC): An individual patient data (IPD) analysis of randomized controlled trials (RCTs) from the ICECaP consortium

Annals of oncology, 2023-10, Vol.34, p.S954-S954

2023

Volltextzugriff (PDF)

1806P Efficacy of niraparib and abiraterone acetate plus prednisone (NIRA+AAP) in homologous recombination repair gene-altered (HRR+) metastatic castration-resistant prostate cancer (mCRPC) by tissue and/or plasma assays in the MAGNITUDE trial

Annals of oncology, 2023-10, Vol.34, p.S976-S977

2023

Volltextzugriff (PDF)

1809P Dynamics of plasma tumour DNA and copy number alterations in advanced metastatic castration-resistant prostate cancer (mCRPC) patients treated with cabazitaxel: A prospective biomarker trial

Annals of oncology, 2023-10, Vol.34, p.S979-S979

2023

Volltextzugriff (PDF)

196 POSTER A phase I trial incorporating the pharmacodynamic (PD) study of circulating tumour cells (CTC) of CP-751,871 (C), a monoclonal antibody against the insulin-like growth factor 1 receptor (IGF-1R), in combination with docetaxel (D) in patients (p) with advanced cancer

European journal of cancer supplements, 2006-11, Vol.4 (12), p.61-62

2006

Volltextzugriff (PDF)

197 A phase I and pharmacokinetic (PK) study of an agonistic, fully human monoclonal antibody, HGS-ETR2, to the TNF-alpha related apoptosis inducing ligand receptor 2 (TRAIL R2) in patients with advanced cancer

European journal of cancer supplements, 2004-09, Vol.2 (8), p.61-61

2004

Volltextzugriff (PDF)

207 - Prostate cancer intra-tumoral heterogeneity: Correlation between clinical parameters, mpMRI and biomarkers

European urology supplements : official journal of the European Association of Urology, 2017-03, Vol.16 (3), p.e358-e359

2017

Volltextzugriff (PDF)

2537 Preliminary findings from PLATO: A two-period, phase 4, randomized, double-blind, placebo-controlled study of continued enzalutamide treatment beyond progression in men with chemotherapy-naïve metastatic castration-resistant prostate cancer (mCRPC)

European journal of cancer (1990), 2015-09, Vol.51, p.S487-S487

2015

Volltextzugriff (PDF)

2558 Impact of PTEN protein loss on response to docetaxel and overall survival (OS) in metastatic castration resistant prostate cancer (mCRPC) patients

European journal of cancer (1990), 2015-09, Vol.51, p.S496-S496

2015

Volltextzugriff (PDF)

2577 The correlation between circulating cell-free AR and CYP17A1 copy number variations and tumor burden estimated by 18F-fluorocholine PET/CT in metastatic castration-resistant prostate cancer patients treated with abiraterone

European journal of cancer (1990), 2015-09, Vol.51, p.S503-S504

2015

Volltextzugriff (PDF)

258MO Niraparib plus abiraterone acetate plus prednisone (NIRA+AAP) as first-line treatment in patients with BRCA+ metastatic castration-resistant prostate cancer (mCRPC): Second interim analysis in the Asian subgroup of the MAGNITUDE study

Annals of oncology, 2023-11, Vol.34, p.S1573-S1574

2023

Volltextzugriff (PDF)

26 INVITED Selective CYP17 inhibition with abiraterone acetate (AA) in castration resistant prostate cancer (CRPC): the Royal Marsden Hospital experience

European journal of cancer supplements, 2008, Vol.6 (12), p.12-12

2008

Volltextzugriff (PDF)

1 – 25 von 713

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(628)
Mit Volltextzugriff
(646)

Publikationsform

2 weitere anzeigen...

Weniger anzeigen...

Sprache

2 weitere anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

Science & Technology
(399)
Life Sciences & Biomedicine
(202)
Physical Sciences
(166)
Humans
(159)
Male
(121)
Exact Sciences And Technology
(120)
Chemistry
(119)
Technology
(84)
Biological And Medical Sciences
(78)
Physics
(75)
Female
(72)
Medical Sciences
(69)
Materials Science
(67)
Oncology
(63)
Middle Aged
(62)
Chemistry, Physical
(61)
Materials Science, Multidisciplinary
(54)
Aged
(53)
Adult
(45)
General And Physical Chemistry
(45)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(8)

Menü

Weitere Dienste

Einstellungen

1033 - The role of abiraterone acetate plus prednisone/prednisolone in high- and low-risk metastatic hormone sensitive prostate cancer

The 12C(p,2p)11B Reaction at 100 MeV

1358O Clinical qualification of transcriptome signatures for advanced prostate cancer (APC) starting androgen deprivation therapy (ADT) with or without abiraterone acetate and prednisolone (AAP): An ancillary study of the STAMPEDE AAP trial

1359MO Differential treatment response with nodal metastases in metastatic hormone-sensitive prostate cancer (mHSPC) and evaluation of nodal (N) burden as a prognostic biomarker: Ancillary studies of the docetaxel and abiraterone acetate and prednisolone (AAP) phase III trials from STAMPEDE

158 POSTER Abiraterone acetate (AA), an irreversible inhibitor of CYP17, has significant and durable anti-tumor activity in both chemotherapy- naive and docetaxel treated castration-resistant prostate cancer (CRPC)

158MO Niraparib with abiraterone acetate and prednisone (NIRA+AAP) as first-line therapy in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) with homologous recombination repair (HRR+) gene alterations: Asian subgroup analysis of the MAGNITUDE study

159 POSTER Re-inducing sensitivity to abiraterone acetate, a novel CYP17 inhibitor with a high level of anti-tumour activity in castration resistant prostrate cancer

1596O Decipher mRNA score for prediction of survival benefit from docetaxel at start of androgen deprivation therapy (ADT) for advanced prostate cancer (PC): An ancillary study of the STAMPEDE docetaxel trials

1647P Clinical validity of plasma DNA testing to identify BRCA-mutated (BRCA+) patients in the MAGNITUDE study

1656TiP The STAMPEDE2 niraparib-abiraterone acetate + prednisolone trial: A phase III, randomised, open-label trial in patients with metastatic prostate cancer (mPC) with a deleterious alteration in a homologous recombination repair (HRR) gene starting androgen deprivation therapy (ADT)

1657TiP The STAMPEDE2 stereotactic ablative body radiotherapy (SABR) trial: A phase III, randomised, open-label trial in patients with newly diagnosed oligometastatic prostate cancer (PC) starting androgen deprivation therapy (ADT)

1658TiP The STAMPEDE2 177Lutetium-PSMA-617 (177Lu-PSMA-617) trial: A phase III, randomised, open-label trial in patients with metastatic prostate cancer (mPC) starting androgen deprivation therapy (ADT)

1767MO External validation of a digital pathology-based multimodal artificial intelligence (MMAI)-derived model in high-risk localized (M0)/metastatic (M1) prostate cancer (PCa) starting androgen deprivation therapy (ADT) in the docetaxel (Doc) or abiraterone (AAP) phase III STAMPEDE trials

1770O Refining risk stratification in patients undergoing radiotherapy (RT) and long-term (lt) ADT for high-risk/locally advanced prostate cancer (HR/LA-PC): An individual patient data (IPD) analysis of randomized controlled trials (RCTs) from the ICECaP consortium

1806P Efficacy of niraparib and abiraterone acetate plus prednisone (NIRA+AAP) in homologous recombination repair gene-altered (HRR+) metastatic castration-resistant prostate cancer (mCRPC) by tissue and/or plasma assays in the MAGNITUDE trial

1809P Dynamics of plasma tumour DNA and copy number alterations in advanced metastatic castration-resistant prostate cancer (mCRPC) patients treated with cabazitaxel: A prospective biomarker trial

1836P Blood based biomarkers identify metastatic castration-resistant prostate cancer (mCRPC) with the greatest benefit from continuing enzalutamide (ENZ) beyond progression in combination with docetaxel (Doc): A pre-specified biomarker study of the phase IIIb PRESIDE trial

196 POSTER A phase I trial incorporating the pharmacodynamic (PD) study of circulating tumour cells (CTC) of CP-751,871 (C), a monoclonal antibody against the insulin-like growth factor 1 receptor (IGF-1R), in combination with docetaxel (D) in patients (p) with advanced cancer

197 A phase I and pharmacokinetic (PK) study of an agonistic, fully human monoclonal antibody, HGS-ETR2, to the TNF-alpha related apoptosis inducing ligand receptor 2 (TRAIL R2) in patients with advanced cancer

207 - Prostate cancer intra-tumoral heterogeneity: Correlation between clinical parameters, mpMRI and biomarkers

2537 Preliminary findings from PLATO: A two-period, phase 4, randomized, double-blind, placebo-controlled study of continued enzalutamide treatment beyond progression in men with chemotherapy-naïve metastatic castration-resistant prostate cancer (mCRPC)

2558 Impact of PTEN protein loss on response to docetaxel and overall survival (OS) in metastatic castration resistant prostate cancer (mCRPC) patients

2577 The correlation between circulating cell-free AR and CYP17A1 copy number variations and tumor burden estimated by 18F-fluorocholine PET/CT in metastatic castration-resistant prostate cancer patients treated with abiraterone

258MO Niraparib plus abiraterone acetate plus prednisone (NIRA+AAP) as first-line treatment in patients with BRCA+ metastatic castration-resistant prostate cancer (mCRPC): Second interim analysis in the Asian subgroup of the MAGNITUDE study

26 INVITED Selective CYP17 inhibition with abiraterone acetate (AA) in castration resistant prostate cancer (CRPC): the Royal Marsden Hospital experience

Suchergebnisse filtern